肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.)(Recombinant anti-TNFα human monoclonal antibody(Alphamab Jilin Co., Ltd.))

概要

基本信息

药物类型

单克隆抗体

别名-

靶点

TNF-α

作用机制

TNF-α抑制剂(肿瘤坏死因子α抑制剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

康宁杰瑞（吉林）生物科技有限公司

在研机构-

非在研机构

康宁杰瑞（吉林）生物科技有限公司

最高研发阶段无进展临床申请

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

100 项与肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

1

项与肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.) 相关的文献（医药）

2024-08-01·Pediatric nephrology (Berlin, Germany)

Adalimumab as a cause of kidney injury in patients with Crohn’s disease

Article

作者: Grenda, Ryszard ; Litwin, Mieczysław ; Obrycki, Łukasz ; Koziej, Jan ; Szymańska, Sylwia ; Skoczyński, Krzysztof

INTRODUCTION:

Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).

CASE DIAGNOSIS/TREATMENT:

We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.

CONCLUSIONS:

Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

100 项与肿瘤坏死因子α重组全人源单抗(Alphamab Jilin Co., Ltd.) 相关的药物交易

登录后查看更多信息